Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1956)	10/31/2007 12:24:04 AM
From: Jibacoa	Respond to of 3722

CRGN Has closed most of its Oct 11 DG, when it announced that velafermin for oral mucositis did not meet its primary endpoint. bigcharts.marketwatch.com Last week it announced that the PI results on CR011 for the treatment of metastatic melanoma showed that CR011 is well-tolerated at doses up through 1.88 mg/kg & no dose-limiting toxicities were noted. Dose- escalation trial has continued with patients now being enrolled into the 2.63 mg/kg cohort. Of the 25 patients that were treated with doses ranging from 0.03 mg/kg to 1.88 mg/kg, 6 patients achieved stable disease lasting up to 11 cycles & 4 of the 6 patients demonstrated tumor shrinkage of up to 20%. Reversible neutropenia was the only drug-related adverse event, and it appeared to be dose-dependent. Upon establishing the MTD, the trial is expected to expand directly into a PII to assess the activity of CR011 in up to 32 patients with Stage III or Stage IV malignant melanoma. CRGN needs to close above 1.60 before it can test its more important resistance at the $2 to $2.06 level.<g> bigcharts.marketwatch.com Bernard